News
Article
Author(s):
The agent, named eVa, can replace multiple tools for marketers.
Stock.adobe.com
One of the most potentially game-changing aspects of AI-based technology is its ability to perform multiple functions. A big issue for the pharmaceutical industry is handling non-normalized data. Multiple teams work on a drug throughout its life cycle, and each one has unique needs. Often, the work that one team does is directly related to the work that another does. However, since both teams are operating with different priorities, it can be difficult to coordinate that work and provide data that is usable for both teams.
With AI, data can be normalized early on and programs can be generated throughout the development process as more data is collected.
Viseven announced a new AI agent for its content creation platform eWizard. The new agent, called eVa, is able to communicate with both marketing and medical teams at pharmaceutical companies. The company bills the program as an all-in-one tool that can be used throughout the development and commercialization process.
In a press release, Viseven describes the program as being able to simplify the process that pharma marketing teams use. Typically, these teams use different tools for different tasks, which can cause delays in the process as teams switch from one tool to another. Since the process isn’t always straightforward, these teams often find themselves switching back-and-forth between tools more than once.
eVa is able to build content that uses brand-approved assets while also checking for compliancy.
This is part of a growing trend in the pharma industry that hopes to use AI to simplify its processes and make as many steps of the development and commercialization process more efficient. These programs are generally being designed not to replace humans, but instead to automate the time-consuming tedious tasks that often slow down the entire process.
According to Viseven,2 it views AI as something that shouldn’t be viewed as an extra step, but included as part of the process. It describes AI as a tool that can do more than just speed up processes. Part of the goal for eVa is to free up marketers to spend their time on the creative, while they use the AI agent to ensure that the work is compliant. The company describes AI as something that doesn’t need to be flashy, but instead a tool that quietly removes obstacles and makes the process simpler.
As an example, Viseven has a client that reportedly spent 2,000 hours-per-year on content production. On top of that, it then spent an additional 500 hour-per-year on rework due to outdated assets or inconsistent formatting. As a result, timelines were impacted and the company would miss deadlines or have to delay campaigns. By using a system that monitors assets and formatting through the entire process, Viseven says that companies can significantly reduce or hopefully even remove the rework process entirely. This way, marketers get to focus on the work that excites them.
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
